Fig. 1: Survival outcomes of primary myelodysplastic syndromes/neoplasms patients stratified by genomic status. | Blood Cancer Journal

Fig. 1: Survival outcomes of primary myelodysplastic syndromes/neoplasms patients stratified by genomic status.

From: Prognostic implications of genetic and transcriptomic abnormalities in MDS according to IPSS-R, IPSS-M, and the International Consensus Classification

Fig. 1: Survival outcomes of primary myelodysplastic syndromes/neoplasms patients stratified by genomic status.

Kaplan–Meier analysis of a leukemia-free survival (LFS) and b overall survival (OS) in patients categorized into four groups: normal karyotype (NK) without gene mutations (n = 155), gene mutations only (n = 299), cytogenetic abnormalities only (n = 62), and concomitant gene mutations and cytogenetic abnormalities (n = 242).

Back to article page